Antidiabetic drugs and neuroendocrine neoplasms: a double-edged sword?

Minerva Med. 2021 Dec;112(6):683-685. doi: 10.23736/S0026-4806.21.07846-0.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Neuroendocrine Tumors* / chemically induced

Substances

  • Hypoglycemic Agents